title: Oxidized low-density lipoprotein is negatively correlated with lecithin-cholesterol acyltransferase activity in type 2 diabetes mellitus.
abstract: BACKGROUND
  It is now believed that the oxidative modification of plasma lipoproteins enhance their atherogenicity in patients with type 2 diabetes. Because a variety of highly reactive lipid peroxidation products can transfer from oxidized low-density lipoprotein (ox-LDL) to high-density lipoprotein -cholesterol, the authors evaluated the association between ox-LDL and lecithin-cholesterol acyltransferase (LCAT) activity, a key enzyme in reverse cholesterol transport and HDL remodeling.
  
  
  METHODS
  A total of 45 patients with diabetes and 45 age-, sex- and body mass index-matched healthy adult volunteers were enrolled. Fasting blood samples were obtained, and plasma glucose, lipid profile, creatinine, insulin, ox-LDL and LCAT activity were measured. Homeostasis model assessment of insulin resistance was also calculated.
  
  
  RESULTS
  Patients with diabetes, compared with healthy participants, had a significantly higher ox-LDL (17.16 ± 3.75 U/L versus 7.93 ± 1.92 U/L, P < 0.001) and lower LCAT activity (73.7 ± 9.1 μmol/L/hr versus 88.7 ± 4.5 μmol/L/hr, P < 0.001). The higher level of LCAT activity completely disappeared after adjustment for ox-LDL. LCAT activity had a significant (P < 0.001) inverse correlation with ox-LDL (r = -0.77) in patients with diabetes and healthy participants (r = -0.75).
  
  
  CONCLUSIONS
  LCAT activity is significantly decreased in type 2 diabetes. The lower LCAT activity in type 2 diabetes might be through ox-LDL mechanism. Ox-LDL may adversely affect high-density lipoprotein -cholesterol metabolism by reducing LCAT activity.
authors.affiliation: Endocrinology and Metabolism Research Center, Vali-Asr Hospital, Tehran University of Medical Sciences, Iran. nakhjavanim@tums.ac.ir
authors.forename: Manouchehr
authors.initials: M
authors.lastname: Nakhjavani
authors.forename: Firouzeh
authors.initials: F
authors.lastname: Asgharani
authors.forename: Omid
authors.initials: O
authors.lastname: Khalilzadeh
authors.forename: Alireza
authors.initials: A
authors.lastname: Esteghamati
authors.forename: Azam
authors.initials: A
authors.lastname: Ghaneei
authors.forename: Afsaneh
authors.initials: A
authors.lastname: Morteza
authors.forename: Mehdi
authors.initials: M
authors.lastname: Anvari
mesh_terms: D000217:Acyltransferases / Q000097:blood*; D002318:Cardiovascular Diseases / Q000097:blood / Q000201:enzymology / Q000209:etiology; D016022:Case-Control Studies; D008076:Cholesterol, HDL / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications / Q000201:enzymology*; D003925:Diabetic Angiopathies / Q000097:blood / Q000201:enzymology / Q000209:etiology; D005260:Female; D049669:History, 16th Century; D049670:History, 17th Century; D006801:Humans; D008077:Lipoproteins, LDL / Q000097:blood*; D008297:Male; D012307:Risk Factors
chemical_list: D008076:Cholesterol, HDL; D008077:Lipoproteins, LDL; C099252:oxidized low density lipoprotein; D000217:Acyltransferases; C056942:lecithin-retinol acyltransferase